ArticleClinical rheumatology2020
Impact of TNF-α inhibitor on lipid profile and atherogenic index of plasma in axial spondyloarthritis: 2-year follow-up data from the Catholic Axial Spondyloarthritis COhort (CASCO).
Article in Clinical rheumatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.
- Cardiovascular risk in axial spondyloarthritis-a systematic review.Clinical rheumatology · 2023Pooled it
- The Effects of Disease-Modifying Antirheumatic Drugs on Cardiovascular Risk in Inflammatory Joint Diseases: Current Evidence and Uncertainties.Vascular health and risk management · 2025Review
- Impact of anti-tumor necrosis factor treatment on lipid profiles in Korean patients with ankylosing spondylitis.Journal of rheumatic diseases · 2024Article
- Interleukin-17-targeted treatment in patients with spondyloarthritis and associated cardiometabolic risk profile.Frontiers in immunology · 2023Review
- Four-year follow-up of atherogenicity in rheumatoid arthritis patients: from the nationwide Korean College of Rheumatology Biologics Registry.Clinical rheumatology · 2021Article
- Effect of Biologics on Cardiovascular Inflammation: Mechanistic Insights and Risk Reduction.Journal of inflammation research · 2021Review
Corrections and comments
- Commented on by
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To evaluate the influence of TNF-α inhibitor on lipid profile and atherogenic index of plasma (AIP) in axial spondyloarthritis (axSpA) patients with long-term use of stable dose TNF-α inhibitor. AxSpA patients were enrolled in the Catholic Axial Spondyloarthritis COhort (CASCO). We collected their data annually and analyzed their lipid profile and AIP. Comparison was conducted between TNF-α inhibitor user group and non-user group. Additionally, lipid profile and AIP of TNF-α inhibitor user group were compared over 2 years. A total of 238 axSpA patients were enrolled for the present study, including 132 TNF-α inhibitor users and 106 non-users. Changes of total cholesterol (TC), TG, low-density lipoprotein cholesterol (LDL-C), and HDL-C over 2 years did not show significant difference between TNF-α inhibitor user group and non-user group. When baseline data and 2-year follow-up data were compared within the TNF-α inhibitor user group, there was no significant increase in TG, LDL-C, HDL-C, or AIP. Only TC level was slightly increased in the 2-year follow-up data for the TNF-α inhibitor user group (177.86 ± 28.73 vs. 183.08 ± 29.82, P = 0.019). Long-term use of stable dose TNF-α inhibitor did not increase atherogenic lipid profile or AIP compared to the control group. Furthermore, atherogenic lipid profile or AIP was not increased significantly in the TNF-α inhibitor user group over the 2-year follow-up. Therefore, using TNF-α inhibitor for a long term might not affect atherosclerosis of axSpA.Key Points• Managing risk factors of cardiovascular disease (CVD) such as dyslipidemia in axSpA is important because axSpA patients have increased risk of CVD.• Using TNF-α inhibitor for 2 years with stable dose did not deteriorate atherogenic lipid profile or AIP as predictor of atherosclerosis.• Maintaining stable dose of TNF-α inhibitor for long-term in axSpA may be relatively safe for managing atherogenic lipid.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.